样本编号	SAMC3543427
外部数据库编号	GSA-Human: HRS1221796
样品名称	SC-T-01053-1_R
样本标题	Ovary
样品类型	Human sample
物种名称	Homo sapiens
描述信息	HGSOC
样本属性	*该样本包含更多受控访问信息，请通过GSA-Human系统申请项目HRA007216数据获取。
发布日期	2025-05-01
项目编号	PRJCA016620
提交者	Qinglei Gao (qingleigao@hotmail.com)
提交单位	Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
提交日期	2024-04-20

样本包含数据信息

资源名称	描述
GSA-Human (1)	-
HRA007216 (Controlled Access)	Ovarian cancer is a serious gynecological malignancy that poses a significant threat to women's life and health, and China has the highest number of patients worldwide. Ovarian cancer is difficult to diagnose early due to lacking symptoms, difficult to classify due to complex types, and difficult to treat due to drug resistance and recurrent. As a result, the 5-year overall survival rate has remained between 30% ~ 40% for over a century. It severely impedes the accomplishment of the arduous task proposed by President Xi that increasing the 5-year survival rate of cancer by 15%, as outlined in the "Healthy China 2030 Plan". Based on the clinic trial NeoAdjuvant Niraparib Therapy (NANT, identifier: NCT04507841), here we investigate the effects of genetic background, tumor microenvironment and their interactions on PARP inhibitor resistance of ovarian cancer through multi omics sequencing.

资源名称

描述

GSA-Human (1)

HRA007216 (Controlled Access)

Ovarian cancer is a serious gynecological malignancy that poses a significant threat to women's life and health, and China has the highest number of patients worldwide. Ovarian cancer is difficult to diagnose early due to lacking symptoms, difficult to classify due to complex types, and difficult to treat due to drug resistance and recurrent. As a result, the 5-year overall survival rate has remained between 30% ~ 40% for over a century. It severely impedes the accomplishment of the arduous task proposed by President Xi that increasing the 5-year survival rate of cancer by 15%, as outlined in the "Healthy China 2030 Plan". Based on the clinic trial NeoAdjuvant Niraparib Therapy (NANT, identifier: NCT04507841), here we investigate the effects of genetic background, tumor microenvironment and their interactions on PARP inhibitor resistance of ovarian cancer through multi omics sequencing.